Fox Chase Cancer Center News

Temple Health today announced the appointment of Robert A. Winn, MD, as the next Cancer Center Director for Fox Chase Cancer Center, marking a defining moment that will shape the future of one of the nation’s leading National Cancer Institute-designated Comprehensive Cancer Centers.

Unlike conventional radiation therapy systems, adaptive radiotherapy creates a new plan for each treatment session, allowing clinicians to deliver larger doses of radiation to tumors more safely.

By aligning treatment with patients’ values and goals, Fox Chase Cancer Center clinicians are infusing Goal Concordant Care into routine practice, partnering with their patients to honor what matters most when facing serious illness.

Fox Chase Cancer Center researchers reported positive results from the trial, known as RETAIN-2, demonstrating that a response-adapted bladder-preservation approach involving neoadjuvant chemoimmunotherapy can be considered in select patients.

Fox Chase Cancer Center researchers found that combining an imaging exam with a particular blood test can help identify which patients still have cancer in their bladder after treatment and which may be cancer-free.

Researchers and clinical nurse researchers at Fox Chase Cancer Center created a program to help kidney cancer patients better understand and feel more comfortable with clinical trials. One goal is to increase diversity in clinical trial enrollment.

Discoveries from Siddharth Balachandran, PhD, reveal how the same immune pathways that fight viruses can be harnessed to make cancer immunotherapy more effective, highlighting the transformative power of basic science.

Khariton joins Fox Chase during a period of sustained growth and integration of its clinical services and research enterprise across Temple Health, the Lewis Katz School of Medicine and Temple University.